Eli Lilly: Health Canada Approves Taltz for Non-Radiographic Axial Spondyloarthritis
October 19 2020 - 9:16AM
Dow Jones News
By Michael Dabaie
Eli Lilly & Co. said Health Canada approved Taltz for the
treatment of adult patients with active non-radiographic axial
spondyloarthritis, or nr-axSpA.
Axial spondyloarthritis, which includes both ankylosing
spondylitis and nr-axSpA, is a disease that predominantly affects
the sacroiliac joints and the spine, which results in chronic
inflammatory back pain and fatigue.
This is the fourth indication for Taltz, which was first
approved by Health Canada for moderate-to-severe plaque psoriasis
in 2016, psoriatic arthritis in 2018, and ankylosing spondylitis in
2020.
"People living with non-radiographic axial spondyloarthritis
suffer through considerable pain and other symptoms of inflammation
for as long as ten years before being accurately diagnosed. Limited
treatment options exacerbate this challenge," said Doron Sagman,
vice president of R&D and medical affairs for Eli Lilly
Canada.
Write to Michael Dabaie at michael.dabaie@wsj.com
(END) Dow Jones Newswires
October 19, 2020 09:01 ET (13:01 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
Eli Lilly (NYSE:LLY)
Historical Stock Chart
From Mar 2024 to Apr 2024
Eli Lilly (NYSE:LLY)
Historical Stock Chart
From Apr 2023 to Apr 2024
